Literature DB >> 25211374

Validation of the GAP score in Korean patients with idiopathic pulmonary fibrosis.

Eun Sun Kim1, Sun Mi Choi1, Jinwoo Lee1, Young Sik Park1, Chang-Hoon Lee1, Jae-Joon Yim1, Chul-Gyu Yoo1, Young Whan Kim1, Sung Koo Han1, Sang-Min Lee2.   

Abstract

BACKGROUND: No study has determined whether the risk of mortality predicted by the GAP (gender, age, and physiologic variables) model matches the observed mortality from idiopathic pulmonary fibrosis (IPF) in non-Western populations. We evaluated the clinical course of IPF and validated the GAP model in Korean patients with IPF.
METHODS: We included 268 patients who received a diagnosis of IPF at Seoul National University Hospital between 2005 and 2009. For each patient, demographics and clinical data, such as lung physiologic parameters at IPF diagnosis, were evaluated. We validated the GAP model using discrimination and calibration to predict the risk of death in Korean patients with IPF.
RESULTS: The study population comprised 181 men and 87 women (mean age, 65.9 years). The mean baseline % predicted FVC was 77, and % predicted diffusing capacity of lung for carbon monoxide was 65.9. A total of 157 deaths (58.6%) occurred during follow-up, and the median time to death was 4.64 years. The observed cumulative mortality at 1, 2, and 3 years was 10.4%, 20.9%, and 31.0%, respectively. The GAP model produced estimates of 1-year mortality risk consistent with the observed data (C statistic: GAP calculator, 0.74; GAP index and staging system, 0.72; P < .29). However, calibration of the GAP model at 3 years was not satisfactory.
CONCLUSIONS: The GAP model showed similar discrimination power compared with the original cohort but did not predict the 3-year risk of death accurately. Further multinational validation studies are needed.

Entities:  

Mesh:

Year:  2015        PMID: 25211374     DOI: 10.1378/chest.14-0453

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  20 in total

1.  The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease.

Authors:  Rebeccah M Brusca; Iago Pinal-Fernandez; Kevin Psoter; Julie J Paik; Jemima Albayda; Christopher Mecoli; Eleni Tiniakou; Andrew L Mammen; Lisa Christopher-Stine; Sonye Danoff; Cheilonda Johnson
Journal:  Respir Med       Date:  2019-02-21       Impact factor: 3.415

2.  Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.

Authors:  Tomoo Kishaba; Hiroaki Nagano; Yuichiro Nei; Shin Yamashiro
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

3.  The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.

Authors:  Julie Morisset; Eric Vittinghoff; Bo Young Lee; Roberto Tonelli; Xiaowen Hu; Brett M Elicker; Jay H Ryu; Kirk D Jones; Stefania Cerri; Andreina Manfredi; Marco Sebastiani; Andrew J Gross; Brett Ley; Paul J Wolters; Talmadge E King; Dong Soon Kim; Harold R Collard; Joyce S Lee
Journal:  Respir Med       Date:  2017-04-22       Impact factor: 3.415

4.  Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.

Authors:  Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee
Journal:  Chest       Date:  2017-06-16       Impact factor: 9.410

5.  Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.

Authors:  Michael T Durheim; Harold R Collard; Rhonda S Roberts; Kevin K Brown; Kevin R Flaherty; Talmadge E King; Scott M Palmer; Ganesh Raghu; Laurie D Snyder; Kevin J Anstrom; Fernando J Martinez
Journal:  Lancet Respir Med       Date:  2015-04-15       Impact factor: 30.700

6.  Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?

Authors:  Hanna M Nurmi; Minna K Purokivi; Miia S Kärkkäinen; Hannu-Pekka Kettunen; Tuomas A Selander; Riitta L Kaarteenaho
Journal:  BMC Pulm Med       Date:  2017-01-13       Impact factor: 3.317

7.  Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis.

Authors:  Miia Kärkkäinen; Hannu-Pekka Kettunen; Hanna Nurmi; Tuomas Selander; Minna Purokivi; Riitta Kaarteenaho
Journal:  Respir Res       Date:  2017-08-22

8.  Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis.

Authors:  Keishi Sugino; Hirotaka Ono; Natsumi Watanabe; Masahiro Ando; Eiyasu Tsuboi; Sakae Homma; Kazuma Kishi
Journal:  BMC Pulm Med       Date:  2021-07-10       Impact factor: 3.317

9.  Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study.

Authors:  Sang Hoon Lee; Song Yee Kim; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Soo Taek Uh; Choon Sik Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jong Wook Shin; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Yong Hyun Kim; Jin Woo Song; Sung Woo Park; Moo Suk Park
Journal:  Respir Res       Date:  2016-10-18

Review 10.  Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations.

Authors:  Yutaro Nakamura; Takafumi Suda
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2016-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.